-
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Tuesday, February 6, 2024 - 9:21am | 194Read More...Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action. The company’s lead...
-
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
Thursday, November 16, 2023 - 9:12am | 734Read More...More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths annually. A potentially revolutionary therapy option could help treat the many...
-
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
Monday, October 30, 2023 - 8:33am | 690Read More...New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments. MAIA Biotechnology Inc. (NYSE: MAIA) is focused on the development and commercialization of drugs that improve and extend the lives of people with...
-
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
Monday, October 16, 2023 - 8:11am | 612Read More...Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. Radiotherapy, the current standard of care, has limitations, including short-lived responses that last about six to nine months on average. Promising new study...
